CBC (cannabichromene) and CBG (cannabigerol) are two non-intoxicating cannabinoids found naturally in the cannabis plant. Neither one produces a high like THC, but both interact with your body’s nervous system in distinct ways. They share a common origin in the plant’s chemistry, yet they differ significantly in how they work, what they’re used for, and how abundant they are in any given cannabis product.
How CBC and CBG Are Made in the Plant
Every major cannabinoid starts as one molecule: cannabigerolic acid, or CBGA. This is why CBG is sometimes called the “mother cannabinoid.” The plant produces CBGA by combining two precursor compounds, geranyl diphosphate and olivetolic acid. From there, enzymes in the plant convert CBGA into the acidic forms of THC, CBD, and CBC. Whatever CBGA doesn’t get converted remains as is.
Heat and drying then strip a carbon dioxide molecule from these acidic forms in a process called decarboxylation. That’s what turns CBGA into CBG, CBCA into CBC, THCA into THC, and so on. Because most CBGA gets funneled into producing other cannabinoids, CBG typically exists only in small quantities in mature cannabis plants, usually around 1% or less. CBC concentrations vary by strain but are also generally low compared to THC and CBD.
How CBG Works in the Body
CBG interacts with both of the main cannabinoid receptors in your body, CB1 and CB2, but weakly. It acts as a weak agonist at CB1 (the receptor THC activates to produce a high) and a partial agonist at CB2, which is concentrated in immune cells. Binding studies show CBG attaches to CB1 with relatively low affinity, around 1,045 nM, compared to THC’s much tighter grip. Its connection to CB2 is slightly better but still modest at roughly 1,225 nM in standard lab assays, though more sensitive testing methods in living cells have measured it as low as 152 nM.
This weak CB1 activity is exactly why CBG doesn’t get you high. But CBG may still influence the CB1 receptor indirectly by slowing the breakdown of anandamide, one of your body’s own cannabinoid-like molecules. The net result is a subtle boost to your endocannabinoid system without the intoxication.
Research in animal models of inflammatory bowel disease found that CBG reduced nitric oxide production in immune cells and eased colitis symptoms, with the effect specifically tied to CB2 receptor activation. A 2024 study also found CBG significantly reduced anxiety in subjects, pointing to potential calming effects through pathways that don’t involve a traditional cannabis high.
How CBC Works in the Body
CBC takes a completely different route through your nervous system. Instead of targeting the CB1 and CB2 receptors, it primarily activates a set of ion channels called TRP channels, which are involved in pain signaling, temperature sensation, and inflammation. CBC is the most potent cannabinoid activator of the TRPA1 channel, with a potency (EC50) of just 90 nanomolar. For context, that’s a remarkably low concentration, meaning very small amounts of CBC can trigger this receptor. It also activates the TRPV1 channel, the same receptor that capsaicin in chili peppers stimulates.
These channels play a key role in how your body processes pain signals. In animal studies, CBC’s pain-relieving effects were blocked when researchers used drugs that shut down CB1, TRPA1, and adenosine A1 receptors, suggesting CBC works through multiple pathways at once. CBC also acts as an antagonist of TRPM8, a cold-sensing channel, which may contribute to its ability to modulate sensory perception.
Anti-Inflammatory Effects of CBC
Lab studies have shown CBC can substantially reduce markers of inflammation. When researchers exposed immune cells to a bacterial toxin and then treated them with CBC, the production of key inflammatory proteins dropped dramatically: IL-1β by about 66%, TNF-α by 67%, and IL-6 by nearly 80% compared to untreated cells. The enzyme iNOS, which drives inflammation by producing nitric oxide, was reduced to about 34% of its normal expression at the highest CBC concentration tested.
In mice, oral CBC at 10 mg/kg reduced iNOS levels by 55% compared to animals given only an inflammation-triggering agent. Inhaled CBC also reduced cytokine production and lung inflammation in a mouse model of acute respiratory distress, with the effects traced to its activation of TRPA1 and TRPV1 channels. Interestingly, CBC did not significantly affect COX-2, the enzyme targeted by common anti-inflammatory drugs like ibuprofen. This suggests CBC works through a different inflammatory pathway than over-the-counter painkillers.
CBC vs. CBG at a Glance
- Primary receptors: CBG works mainly through CB1 and CB2 cannabinoid receptors (weakly). CBC works mainly through TRP ion channels, especially TRPA1.
- Psychoactive effects: Neither produces a high. CBG’s CB1 activity is far too weak to cause intoxication.
- Plant abundance: Both are minor cannabinoids, typically present at 1% or less in most cannabis strains. CBG levels are low because the plant converts most of its precursor into other cannabinoids.
- Inflammation: Both show anti-inflammatory potential, but through different mechanisms. CBG works through CB2 receptors on immune cells. CBC works through TRP channels and reduces specific inflammatory proteins.
- Pain: CBC has more direct evidence for pain relief through its potent TRPA1 activation. CBG’s pain-related research is less developed.
The Entourage Effect With Other Cannabinoids
Both CBC and CBG may be more effective when combined with THC and CBD rather than used alone. This concept, known as the entourage effect, suggests that cannabinoids, terpenes, and other plant compounds work together to produce stronger or broader effects than any single compound.
A study testing a 1:1:1 ratio of CBD, THC, and CBG found enhanced potency and greater effectiveness at reducing pain responses compared to individual cannabinoids. Higher CBG-to-THC ratios appeared to dampen THC’s psychoactive effects, while higher THC-to-CBG ratios increased them. This means CBG may serve a similar role to CBD in tempering the intensity of a THC experience. A 2021 review found that combining CBD with CBG, or THC with CBD, significantly reduced inflammatory markers, while THC alone did not achieve the same effect.
For people interested in the therapeutic potential of cannabis without strong psychoactive effects, products that combine CBD with CBG or CBC in a full-spectrum formulation may offer broader benefits than CBD isolate alone.
Safety and Side Effects
Neither CBC nor CBG has been the subject of large-scale human safety trials, so most of what we know about cannabinoid safety comes from research on CBD, the most studied non-intoxicating cannabinoid. CBD has been well tolerated in humans at doses up to 1,500 mg per day, with the most common side effects being tiredness, diarrhea, and changes in appetite or weight. It does not alter blood pressure, heart rate, body temperature, or psychological function at typical doses.
CBC and CBG are expected to share a similar safety profile given their non-intoxicating nature and lower typical doses, but that assumption hasn’t been rigorously confirmed. One area of caution for all cannabinoids is drug interactions. Cannabinoids can inhibit certain liver enzymes and drug transporters that process medications, potentially changing how quickly your body clears other drugs. If you take prescription medications, this is worth discussing with a pharmacist before adding any cannabinoid supplement.
Legal Status in the United States
Under the 2018 Farm Bill, hemp-derived cannabinoids including CBC and CBG are federally legal as long as they come from cannabis plants containing no more than 0.3% THC on a dry-weight basis. Recent federal updates have tightened the definition further: synthetic cannabinoids, meaning those manufactured or chemically converted outside the plant (like delta-8 THC derived from CBD), now fall outside the legal definition of hemp and could face Controlled Substances Act restrictions.
Naturally occurring CBC and CBG extracted directly from hemp are not affected by this synthetic cannabinoid restriction. However, state laws vary. Some states regulate all cannabinoid products regardless of THC content, so checking your state’s specific rules before purchasing is worth the effort.